Nuwellis, Inc.

Nuwellis, Inc. announced a Special Meeting of Stockholders on July 24, 2026, to vote on key corporate actions. Shareholders will consider approving a reverse stock split at a ratio between 1-for-5 and 1-for-70 to maintain Nasdaq listing compliance. Additionally, approval is sought for the issuance of up to 2,396,709 shares upon the exercise of warrants, which could generate approximately $18.3 million in proceeds crucial for funding operations. The Board unanimously recommends approval for all proposals.

Nuwellis, Inc. announced the five-year anniversary of its support for the Pediatric Cardiac Critical Care Consortium (PC4), an alliance focused on improving care for pediatric and congenital cardiovascular disease. The company has collaborated with leading institutions to advance clinician education, scientific exchange, and awareness of fluid management strategies in critically ill children. Nuwellis' Aquadex SmartFlow system is used in many leading pediatric cardiac centers to manage fluid overload, underscoring the company's commitment to the pediatric market.

Nuwellis, Inc. announced Mike McCormick will assume the role of Chief Executive Officer on June 30, 2026, with John Erb transitioning to Chairman of the Board. The company reported strong Q1 2026 results, including 26% year-over-year revenue growth and a 70.1% gross margin. Nuwellis also outlined strategic priorities, including the acquisition of Rendiatech, Inc. to expand its critical care platform, and efforts to broaden the Aquadex pediatric indication to smaller patients. The company aims for continued double-digit revenue growth, margin expansion, and disciplined capital allocation.

Nuwellis, Inc. announced a one-for-thirty-five reverse stock split of its common stock, approved by the Board on June 16, 2026. The company filed a Certificate of Amendment on June 23, 2026, with the reverse split becoming effective on June 25, 2026. Trading on a split-adjusted basis will commence on June 26, 2026, under the existing Nasdaq symbol "NUWE".

Nuwellis, Inc. highlighted its Aquadex SmartFlow system at the 4th annual Critical Care Cardiology Education Summit (CCCES), hosted by the University of Minnesota. Over 280 physicians completed hands-on training with the company's ultrafiltration technology, marking a significant educational initiative for cardiac intensivists. Nuwellis aims to advance physician education and expand awareness of its innovative fluid management strategies for critically ill patients.

Nuwellis, Inc. announced the appointment of Mike McCormick as its new Chief Executive Officer, effective June 30, 2026. Current President, CEO, and Chairman, John Erb, will transition from his executive leadership role but will continue to serve as Chairman of the Board. McCormick, a seasoned medical technology executive with over three decades of experience, previously served on Nuwellis's Board and is expected to lead the company into its next phase of growth, focusing on commercial execution and pipeline advancement.

Nuwellis, Inc. announced the closing of its registered public offering on June 8, 2026, which generated gross proceeds of approximately $6.0 million before deducting offering expenses. The offering involved the issuance of 1,903,338 shares of common stock, pre-funded warrants to purchase 18,096,662 shares, and accompanying Series C and D Warrants. Following the exercise of pre-funded warrants, the company reported 12,750,321 shares of common stock issued and outstanding as of June 9, 2026.

Nuwellis, Inc. announced an expanded collaboration with a major South Carolina healthcare system to integrate its Aquadex SmartFlow devices into a children's hospital. The healthcare provider also upgraded to the latest Aquadex devices at two existing facilities. This move validates Nuwellis' ultrafiltration system as a clinically important solution for fluid overload, reinforcing its leadership in the pediatric category. Additionally, Nuwellis recently completed a pre-submission meeting with the FDA to propose expanding the Aquadex SmartFlow System's label to include pediatric patients weighing 5 kg and above, with anticipated submission by year-end 2026.

Nuwellis, Inc. announced the closing of its public offering, raising approximately $6.0 million in gross proceeds. The offering included 1,903,338 shares of common stock and 18,096,662 pre-funded warrants, each accompanied by Series C and Series D Warrants. The common stock and accompanying warrants were priced at $0.30 per unit, while pre-funded warrants and accompanying warrants were priced at $0.2999 per unit. The Series C and D Warrants are exercisable at $0.30 following stockholder approval and a reverse stock split.

Nuwellis, Inc. announced the pricing of a public offering, aiming to raise approximately $6 million in gross proceeds. The offering consists of 20,000,000 shares of common stock (or pre-funded warrants) with accompanying Series C and Series D Warrants, priced at $0.30 per share and warrant. Both warrant series have an exercise price of $0.30, with Series C including a reset clause and Series D a zero cash exercise option, all subject to stockholder approval and a reverse stock split. Additionally, the company conducted a concurrent private placement to reprice existing warrants to $0.30.